Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.
Fiche publication
Date publication
avril 2014
Journal
Breast (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr NERICH Virginie, Pr PIVOT Xavier
Tous les auteurs :
Fiteni F, Villanueva C, Bazan F, Perrin S, Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V, Limat S, Pivot X
Lien Pubmed
Résumé
Trastuzumab in Human Epidermal growth Receptor 2-positive (HER2+) metastatic breast cancer (MBC) was established as standard therapy since 2001. The objective of this study was to search for significant prognostic factors in patients with HER2+ MBC treated by trastuzumab taking into account the institution where the treatment was given.
Mots clés
Aged, Antibodies, Monoclonal, Humanized, therapeutic use, Antineoplastic Agents, therapeutic use, Breast Neoplasms, drug therapy, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Metastasis, Prognosis, Proportional Hazards Models, Survival Analysis, Trastuzumab, Treatment Outcome
Référence
Breast. 2014 Apr;23(2):165-9